Delta4

Delta4 | AI Drug Discovery

Leveraging AI to discover new indications for drugs with known safety profiles.

What We Do

Delta4 is an AI drug discovery biotech company.

We focus on discovering undetected relationships between drugs with a known safety profile and diseases to identify new indications. We do this by utilizing Hyper-C, our artificial intelligence powered platform that allows us to detect these relationships with unprecedented speed.

Hyper-C is operated by our team of highly skilled computational biologists that carefully analyze the data to produce unique insights and opportunities.

The results are new therapy options that find their way to patients faster, more cost-effectively, and more efficiently than ever before.

Hyper-C | Our Platform

Intelligent systems for unparalleled results.

Hyper-C stands for Hyper Connectivity. It’s our proprietary AI platform housing an enormous collection of algorithmic intelligence.

The platform feeds on big data and uses its algorithms and data integration to build molecular models which go through an iterative refinement process matching them to diseases. This sophisticated process utilizing thousands of pre-computed models effectively matches compounds to diseases for more efficient biological testing and clinical trials.

Hyper-C is unique in that unlike other AI platforms, it eliminates the black box problem. Its results provide a clear mechanism of action hypothesis that aids in regulatory requirements.

In-silico AI platform
De-risking with existing safety profiles
70 man-years of development
In-silico AI platform
De-risking with existing safety profiles
70 man-years of development
Learn more about our platform, the exceptional team that operates it, and how it can help you identify new indications for compounds with a higher probability of success in the biological testing and clinical phases.

Our Process

An efficient and cost-effective methodology streamlined for success

While Hyper-C's AI makes it one of the most formidable tools on the market for repurposing drugs with known safety profiles, it's still only a tool.
Delta4's success lies in its powerful 7-step drug discovery process to efficiently and cost-effectively develop assets.
Our approach combines the best of state-of-the-art artificial intelligence in drug discovery with the invaluable skills of our talented computational biologists.
The process begins by harvesting high-quality data on potential drug candidates, chemical structures, and human diseases that Hyper-C integrates through an iterative process to build molecular models.
Once Hyper-C generates a shortlist of proposed matches, our team reviews the data to identify the best candidates to move on to the biological testing (in-vitro/in-vivo) phase and then clinical testing.
Our drug development process reliably gets drugs to market faster and more reliably than ever before.
Previous
Next
Learn more about our process and our pipeline of assets to see what we’re working on.

Who We Are

Crafting the treatments of the future.

Delta4 is a biotech company focused on discovering new indications for existing drugs with known safety profiles.

We accelerate new treatment options to improve the health of patients and get them into their hands faster, more safely, and more efficiently than the traditional approach.

scientist at the computer

Our Partners & Clients

Latest News & Events

Stay up to date with all our activities

From the latest news and press releases to blog posts and important industry events, check here to stay current with what we’re up to and what we’re watching.
Delta team

Delta4 joins the EU-funded COST action PerMediK (Personalized medicine in chronic kidney disease: improved outcome based on Big Data)

The scientific aim of PerMediK is to support the development of a path towards personalized medicine in chronic kidney disease …

Read More →
Kurt Herpel, CEO of Delta4, and Revital Rattenbach, CEO of 4P-Pharma, celebrating the signature of a partnership agreement between Delta4 and 4P-Pharma in Paris (France).

4P-Pharma and Delta4 join forces to find and develop treatments for a rare autoimmune chronic liver disease

Paris (France) and Vienna (Austria), 31st May 2022 – 4P-Pharma, a French clinical stage biotechnology company, and Delta4, an Austrian …

Read More →
clinical trial consultation

Delta4, in preparation for the first clinical study, focused on FSGS

Focal Segmental Glomerulosclerosis (FSGS) is a devastating clinical condition with defined glomerular histopathology and yet a multifaceted pathophysiological, histological and …

Read More →

Get Involved

Learn how you can contribute to the exciting work happening at Delta4

Careers

Forging the innovative treatments of the future requires brilliant minds and we’re always on the lookout for talent.

Investors

Contact us to find out more about how you can invest with us and be a part of pioneering the next successful treatment.

Medical Community

Learn how you can partner with us and combine our technology with your knowledge to develop treatments faster.